Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Migraine

  Free Subscription


31.05.2021

1 Acta Neurol Scand
1 BMC Neurol
2 Headache
2 Nat Rev Neurol
1 Rev Neurol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Neurol Scand

  1. D'AMICO D, Grazzi L, Guastafierro E, Sansone E, et al
    Withdrawal failure in patients with chronic migraine and medication overuse headache.
    Acta Neurol Scand. 2021 May 25. doi: 10.1111/ane.13475.
    PubMed         Abstract available


    BMC Neurol

  2. ALI EN, Carle CF, Lueck CJ, Kolic M, et al
    Assessing migraine patients with multifocal pupillographic objective perimetry.
    BMC Neurol. 2021;21:211.
    PubMed         Abstract available


    Headache

  3. CHIANG CC, Halker Singh R, Lalvani N, Shubin Stein K, et al
    Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study.
    Headache. 2021 May 21. doi: 10.1111/head.14110.
    PubMed         Abstract available

  4. POPOFF E, Johnston K, Croop R, Thiry A, et al
    Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Headache. 2021 May 22. doi: 10.1111/head.14128.
    PubMed         Abstract available


    Nat Rev Neurol

  5. RAPOPORT AM, Lipton RB
    Potassium channel openers - novel triggers of aura and migraine.
    Nat Rev Neurol. 2021 May 26. pii: 10.1038/s41582-021-00517.
    PubMed        

  6. ABU-ARAFEH I, Gelfand AA
    The childhood migraine syndrome.
    Nat Rev Neurol. 2021 May 26. pii: 10.1038/s41582-021-00497.
    PubMed         Abstract available


    Rev Neurol

  7. MARIN-GRACIA M, Hernando-Quintana N, Lopez-Bravo A, Garcia-Arguedas C, et al
    [Degree of compliance with treatment at three months in migraine patients].
    Rev Neurol. 2021;72:377-383.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: